Completed PHASE2 INTERVENTIONAL 1-arm NCT00079391

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peri-transplant Cyclosporine on Chimerism

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Bone Marrow Transplant Rejection Hematologic Malignancies

Interventions allogeneic hematopoietic stem cell transplantation

Updated 6 times since 2017 Last updated: Oct 5, 2015 Started: Jan 31, 2004 Primary completion: Dec 31, 2008 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00079391, this PHASE2 trial focuses on Bone Marrow Transplant Rejection and Hematologic Malignancies and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States